Afro-BiomeDx (AfDX) is a privately-run biomedical company created to serve the continent of Africa in disease diagnosis. We are committed to provide both fee-for-service diagnosis as well as developing novel diagnostic tests to serve the greater continent. AfDX promotes laboratory medicine by empowering medical doctors and patients to take quick actions and make use of real-time diagnosis of diseases, recognizing that clinical symptoms can afford just so much reliability.
Most diseases have overlapping symptoms and without accurate diagnosis a wrong treatment could be offered for a wrong disease. Our diagnostic insights draw from world renowned experts and AfDX is proud to be at the frontline of innovative diagnostic solutions that serve the continent with commitment to:
1. Provide excellent customer service to patients and hospitals.
2. Provide accurate diagnosis with record turn-around time.
3. Provide an online platform that allows clinics, hospitals, private and public healthcare service providers to submit requests and access results in real-time.
At Afro-BiomeDX, we are committed to reduce disease-burden on the continent by revolutionizing the diagnosis of most infectious diseases that are indigenous to the region, as well as paving the way of local manufacturing of user-friendly diagnostic test kits suitable for the environment.
Our goal is to improve healthcare services by enabling physicians make better clinical choices and informed decisions. Our testing profile ranges from serological to molecular-based tests covering both simple and sophisticated tests.
Afro-BiomeDX, in partnership with Innovative Biotech, are in the process of acquiring a license for HIV Multiplex technology from the National Institutes of Health (NIH). This novel technology was developed by the U.S. Centers for Disease Control and Prevention (CDC). The HIV multiplex assay is vital in conducting mass screening of community members especially in high risk populations such as pregnant women, people who inject drugs and other key populations.
The HIV Triplex assay uses plasma, serum and dried blot spots (DBS) and can diagnose HIV-1, serotype HIV-2 and differentiate between recent and long-term infections using a single specimen. Using available resources and this novel techniques, Afro-BiomeDX plans to optimize this assay to add more pathogens in the multiplex format which will drastically reduce the cost of testing to sustainable levels.
Together with our partners, we believe this assay will widely be available across the African continent adding value to the quality of diagnosis while contributing to multiple disease surveillance activities currently taking place.